Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-04. Numbers and descriptions here follow the published literature rather than marketing material.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Abrasion Acrocyanosis Actinic prurigo (familial polymorphous light eruption of American Indians, hereditary polymorphous light eruption of American Indians, Hutchinson's summer prurigo, hydroa aestivale) Aerosol burn Benign summer light eruption Beryllium granuloma Black heel and palm (black heel, calcaneal petechiae, chromidrose plantaire, post-traumatic punctate intraepidermal hemorrhage, tache noir) Callus (callosity, clavus, corn, heloma, heloma durum, heloma molle, intractable plantar keratosis, tyloma) Carbon stain Chilblains (pernio, perniosis) Chronic actinic dermatitis (actinic reticuloid, chronic photosensitivity dermatitis, persistent light reactivity, photosensitive eczema) Colloid milium Coma blister Delayed blister Dermatosis neglecta Edema blister (edema bulla, hydrostatic bulla, stasis blister) Electrical burn Equestrian perniosis Erythema ab igne (fire stains, toasted skin syndrome) Erythrocyanosis crurum Favre–Racouchot syndrome (Favre–Racouchot disease, nodular cutaneous elastosis with cysts and comedones) Foreign body reaction Fracture blister Friction blister Frostbite Garrod's pad (violinist's pad) Harpist's finger Heel stick wound Heat edema Hot tar burn Hunan hand syndrome (chili burn) Hydroa vacciniforme (Bazin's hydroa vacciniforme) Jogger's nipple Juvenile spring eruption Kairo cancer Kang cancer Kangri ulcer Lightning burn Loop mark Magnetic resonance imaging burn (MRI burn) Mercury granuloma Miliaria crystallina (miliaria crystalline, sudamina) Miliaria profunda (mammillaria) Miliaria pustulosa Miliaria rubra (heat rash, prickly heat) Narcotic dermopathy Occlusion miliaria Painful fat herniation (painful piezogenic pedal papules, piezogenic papules) Peat fire cancer Photoaging (dermatoheliosis) Photosensitivity with HIV infection Phototoxic tar dermatitis Photosenitization Phytophotodermatitis (Berloque dermatitis) Pinch mark Polymorphous light eruption (polymorphic light eruption) Postmiliarial hypohidrosis Postoperative hematoma Pressure ulcer (decubitus ulcer) Pseudoacanthosis nigricans Pseudoverrucous papules and nodules Pulling boat hands PUVA-induced acrobullous dermatosis Runner's rump Sclerosing lymphangiitis Silica granuloma Silicone granuloma Skin pop scar Skin track Slap mark Solar erythema Soot tattoo Subcutaneous emphysema Sucking blister Sunburn Hell's itch Surfer's knots Talon noir Tattoo Tennis toe Thermal burn Traumatic asphyxia Trench foot Tropical anhidrotic asthenia Tropical immersion foot (paddy foot, paddy-field foot) Turf toe Uranium dermatosis UV-sensitive syndrome Vibration white finger (dead finger, hand–arm vibration syndrome) Warm water immersion foot Weathering nodule of ear Wrestler's ear (cauliflower ear, traumatic auricular hematoma) Zirconium granuloma
Treatment depends on the underlying cause. In general, exercise, particularly of the aerobic type, is effective for preventing ED during midlife. Counseling can be used if the underlying cause is psychological, including how to lower stress or anxiety related to sex. Medications by mouth and vacuum erection devices are first-line treatments, followed by injections of drugs into the penis, as well as penile implants. Vascular reconstructive surgeries are beneficial in certain groups. Treatments, other than surgery, do not fix the underlying physiological problem, but are used as needed before sex.
== Charity and volunteer work == In 1994, Kermani founded a language and cultural center in his parents' hometown of Isfahan, which he ran until 1997, the year the center had to close due to deteriorating German-Iranian relations. Since fall of 2014, Kermani has been serving as a patron of the initiative Willkommen für Flüchtlinge [Welcome to Refugees] via the Ehrenamt and Flüchtlinge [Volunteering and Refugees] project run by the Kölner Freiwilligenagentur [Cologne Volunteer Agency] which coordinates its offerings with the Kölner Flüchtlingsrat [Cologne Refugee Council].
Vladimir Baranov is a Soviet born Canadian scientist and one of the original co-inventors of Mass cytometry technology... He co-founded DVS Sciences in 2004 (acquired by Fluidigm in 2014 and then renamed to Standard BioTools in 2022) along with Dmitry Bandura, Scott D. Tanner and Olga Ornatsky.
== Publications == The ISI identified cold fusion as the scientific topic with the largest number of published papers in 1989, of all scientific disciplines. The Nobel Laureate Julian Schwinger declared himself a supporter of cold fusion in the fall of 1989, after much of the response to the initial reports had turned negative. He tried to publish his theoretical paper "Cold Fusion: A Hypothesis" in Physical Review Letters, but the peer reviewers rejected it so harshly that he felt deeply insulted, and he resigned from the American Physical Society (publisher of PRL) in protest. The number of papers sharply declined after 1990 because of two simultaneous phenomena: first, scientists abandoned the field; second, journal editors declined to review new papers. Consequently, cold fusion fell off the ISI charts. Researchers who got negative results turned their backs on the field; those who continued to publish were simply ignored. A 1993 paper in Physics Letters A was the last paper published by Fleischmann, and "one of the last reports [by Fleischmann] to be formally challenged on technical grounds by a cold fusion skeptic." The Journal of Fusion Technology (FT) established a permanent feature in 1990 for cold fusion papers, publishing over a dozen papers per year and giving a mainstream outlet for cold fusion researchers. When editor-in-chief George H. Miley retired in 2001, the journal stopped accepting new cold fusion papers.
Sources: en.wikipedia.org
=== Patenting === In the U.S., efforts into creating a chimeric entity appeared to be legal when the topic first came up. Developmental biologist Stuart Newman, a professor at New York Medical College in Valhalla, N.Y., applied for a patent on a human-animal chimera in 1997 as a challenge to the U.S. Patent and Trademark Office and the U.S. Congress, motivated by his moral and scientific opposition to the notion that living things can be patented at all. Prior legal precedent had established that genetically engineered entities, in general, could be patented, even if they were based on beings occurring in nature. After a seven-year process, Newman's patent finally received a flat rejection. The legal process had created a paper trail of arguments, giving Newman what he claimed was a victory. The Washington Post ran an article on the controversy that stated that it had raised "profound questions about the differences—and similarities—between humans and other animals, and the limits of treating animals as property."
=== Blood Loss === In response to significant blood loss, either acute (e.g., trauma or surgery) or chronic (e.g., gastrointestinal bleeding), the bone marrow increases production to replace lost red blood cells. This results in an increased reticulocyte count, as new immature cells are released and make up a larger proportion of the blood volume.
== History and synthesis == DMF was first obtained in 1893 by the French chemist Albert Verley (1867–1959), by distilling a mixture of dimethylamine hydrochloride and potassium formate. It is now industrially manufactured by combining methyl formate and dimethylamine or by reaction of dimethylamine with carbon monoxide. Although currently impractical, DMF can be prepared from supercritical carbon dioxide using ruthenium-based catalysts.
The Bradford assay, a colorimetric protein assay, is based on an absorbance shift of the dye Coomassie brilliant blue G-250. The Coomassie brilliant blue G-250 dye exists in three forms: anionic (blue), neutral (green), and cationic (red). Under acidic conditions, the dye is red; when it is deprotonated, the red form of the dye is converted into its blue form, which can bind to the protein being assayed. If there is no protein present, then the solution will remain brown. Dye-protein interactions are driven by electrostatic interactions between positively charged arginine (and to a lesser extent, lysine and histidine) and the deprotonated negatively charged sulfonate groups on the dye, as well as hydrophobic interactions with the aromatic amino acids (tryptophan, tyrosine, phenylalanine). Binding of the dye to the protein stabilizes the anionic form of the dye, which can be detected colorimetrically by a shift from 465 nm to 595 nm. The cationic (unbound) form is red and has an absorption spectrum maximum at 465 nm, whereas the anionic bound form has an absorption spectrum maximum at 595 nm. The increase of absorbance at 595 nm is proportional to the amount of bound dye, and thus to the amount (concentration) of protein present in the sample. Unlike other protein assays, the Bradford protein assay is less susceptible to interference by various chemical compounds such as sodium, potassium or even carbohydrates like sucrose, that may be present in protein samples. An exception of note is elevated concentrations of detergent.
Deficiency of VWF, therefore, shows primarily in organs with extensive small vessels, such as skin, gastrointestinal tract, and uterus. In angiodysplasia, a form of telangiectasia of the colon, shear stress is much higher than in average capillaries, and the risk of bleeding is increased concomitantly. In more severe cases of type 1 VWD, genetic changes are common within the VWF gene and are highly penetrant. In milder cases of type 1 VWD, a complex spectrum of molecular pathology may exist in addition to polymorphisms of the VWF gene alone. The individual's ABO blood group can influence presentation and pathology of VWD. Those individuals with blood group O have a lower mean level than individuals with other blood groups. Unless ABO group-specific VWF:antigen reference ranges are used, normal group O individuals can be diagnosed as type I VWD, and some individuals of blood group AB with a genetic defect of VWF may have the diagnosis overlooked because VWF levels are elevated due to blood group.
Sources: en.wikipedia.org
The English word for tanning is from the medieval Latin verb tannāre, from the noun tannum (oak bark). This term may be derived from a Celtic word related to the Proto-Indo-European *dʰonu meaning 'fir tree'. (The same root is the source for Old High German tanna meaning 'fir', related to modern German Tannenbaum). Hide clothing, footwear, and shelters have been used since the Paleolithic, with evidence of leather working dated to approximately 400,000 years ago; leather working tools from this period being found at Hoxne, England dating to about 400,000 years ago. Extant vegetable oil tanned leather footwear, from the neolithic (c. 5,500-year-old), has been found in Areni-1 cave, of Vayots Dzor province of Armenia and on the remains of the Ötzi corpse, found on the Austria-Italy border. Ancient civilizations used leather for waterskins, bags, harnesses and tack, boats, armour, quivers, scabbards, boots, and sandals. Tanning was being carried out by the inhabitants of Mehrgarh in Pakistan between 7000 and 3300 BCE. Around 2500 BCE, the Sumerians began using leather, affixed by copper studs, on chariot wheels. The process of tanning was also used for boats and fishing vessels: ropes, nets, and sails were tanned using tree bark. Formerly, tanning was considered a noxious or "odoriferous trade" and relegated to the outskirts of town, among the poor. Tanning by ancient methods is so foul-smelling that tanneries are still isolated from those towns today where the old methods are used. Skins typically arrived at the tannery dried stiff and dirty with soil and gore.
=== Wound repair versus regeneration === An injury is an interruption of morphology and/or functionality of a given tissue. After injury, structural tissue heals with incomplete or complete regeneration. Tissue without an interruption to the morphology almost always completely regenerates. An example of complete regeneration without an interruption of the morphology is non-injured tissue, such as skin. Non-injured skin has a continued replacement and regeneration of cells which always results in complete regeneration. There is a subtle distinction between 'repair' and 'regeneration'. Repair means incomplete regeneration. Repair or incomplete regeneration, refers to the physiologic adaptation of an organ after injury in an effort to re-establish continuity without regards to exact replacement of lost/damaged tissue. True tissue regeneration or complete regeneration, refers to the replacement of lost/damaged tissue with an 'exact' copy, such that both morphology and functionality are completely restored. Though after injury mammals can completely regenerate spontaneously, they usually do not completely regenerate. An example of a tissue regenerating completely after an interruption of morphology is the endometrium; the endometrium after the process of breakdown via the menstruation cycle heals with complete regeneration. In some instances, after a tissue breakdown, such as in skin, a regeneration closer to complete regeneration may be induced by the use of biodegradable (collagen-glycoaminoglycan) scaffolds.
=== Purification === High thorium concentrations are needed in nuclear applications. In particular, concentrations of atoms with high neutron capture cross-sections must be very low (for example, gadolinium concentrations must be lower than one part per million by weight). Previously, repeated dissolution and recrystallisation was used to achieve high purity. Today, liquid solvent extraction procedures involving selective complexation of Th4+ are used. For example, following alkaline digestion and the removal of phosphate, the resulting nitrato complexes of thorium, uranium, and the rare earths can be separated by extraction with tributyl phosphate in kerosene.
== Pharmacology == Nateglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the β cells. This depolarizes the β cells and causes voltage-gated calcium channels to open. The resulting calcium influx induces fusion of insulin-containing vesicles with the cell membrane, and insulin secretion occurs.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.